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A B S T R A C T
Background: Overdiagnosis by mammographic screening is deﬁned as the excess in breast cancer
incidence in the presence of screening compared to the incidence in the absence of screening. The latter is
often estimated by extrapolating the pre-screening incidence trend. The aim of this theoretical study is to
investigate the impact of assumptions in extrapolating the pre-screening incidence trend of invasive
breast cancer on the estimated percentage of overdiagnosis.
Methods: We extracted data on invasive breast cancer incidence and person-years by calendar year
(1975–2009) and 5-year age groups (0–85 years) from Dutch databases. Different combinations of
assumptions for extrapolating the pre-screening period were investigated, such as variations in the type
of regression model, end of the pre-screening period, screened age range, post-screening age range and
adjustment for a trend in women <45. This resulted in 69,120 estimates of the percentage of
overdiagnosis, i.e. excess cancer incidence in the presence of screening as a proportion of the number of
screen-detected and interval cancers.
Results: Most overdiagnosis percentages are overestimated because of inadequate adjustment for lead
time. The overdiagnosis estimates range between7.1% and 65.1%, with a median of 33.6%. The choice of
pre-screening period has the largest inﬂuence on the estimated percentage of overdiagnosis: themedian
estimate is 17.1% for extrapolations using 1975–1986 as the pre-screening period and 44.7% for
extrapolations using 1975–1988 as the pre-screening period.
Conclusion: The results of this theoretical study most likely cover the true overdiagnosis estimate, which
is unknown, andmay not necessarily represent themedian overdiagnosis estimate. This study shows that
overdiagnosis estimates heavily depend on the assumptions made in extrapolating the incidence in the
pre-screening period, especially on the choice of the pre-screening period. These limitations should be
acknowledged when adopting this approach to estimate overdiagnosis.
ã 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Mammographic screening beneﬁts some women and harms a
number of others [1,2]. The major beneﬁt of mammographic
screening is the prevention of breast cancer deaths [1] by detecting
breast cancers at an early stage with better treatment outcomes
[3]. However, a major drawback ofmammographic screening is the
detection of cancers that would not be clinically detected during a
woman’s lifetime if screening had not occurred, i.e. overdiagnosed
cancers.
There is much debate on the extent of overdiagnosis in
mammographic screening, with estimates ranging from 0 to 57%
[4,5]. According to Carter et al. [6], ecological and cohort studies are
the most suitable method for estimating overdiagnosis. There is,
however, awide variability in the design of these studies,which are
related to the methods used to adjust for lead time and the choice
of the unscreened reference population [6]. The unscreened
reference population is often obtained through extrapolating the
incidence in the pre-screening period [5,7–10]. However, studies
utilize different assumptions in order to estimate the pre-
screening incidence trend [11]. Some studies apply linear
regression to incidence rates, while others apply poisson regres-
sion to absolute numbers. Furthermore, studies differ in the age
groups modeled, choice of pre-screening period and whether to
adjust for a trend in non-screened ages.
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The Independent UK Panel on Breast Cancer Screening [11]
estimated the absolute number of overdiagnosed cases in the UK
National Health Service breast cancer screening program using
several different assumptions. They showed that the estimated
number of overdiagnosed cases depends on the speciﬁcation of the
model used for the estimation. Although this indicates that the
choice of the model inﬂuences the estimated percentage of
overdiagnosis, the panel only discussed the effects of a limited
number of model assumptions. Furthermore, the percentage of
overdiagnosis does not only depend on the estimated number of
overdiagnosed cases, but also on the number of cancers in the
denominator [12]. Therefore, this theoretical study investigates the
inﬂuence of a large number of assumptions in extrapolating pre-
screening incidence trends on the estimated percentage of
overdiagnosis by mammographic screening in the Netherlands.
2. Methods
2.1. Setting
In 1989, a biennial mammographic screening program was
gradually implemented in the Netherlands, inviting women aged
50–69 years. Nationwide full coveragewas reached in 1997 and the
upper age limit was gradually extended to age 75 in the period
1998–2001. Because women are invited per region and receive
their ﬁrst invitation in the year they turn 50, 51 or 52, women aged
49 can be screened. The attendance rates in the Dutch program
have always been high, ranging from72% in 1990 to about 80% from
1997 onwards [13]. Until 2014, initial screens consisted of two view
mammography and subsequent screens of one view, an oblique
view, unless a second cranio-caudal view was required. From
2014 onwards, two view mammography became the standard for
subsequent screening. Mammograms are independently read by
two radiologists who decide in consensus on recall. Digital
mammography was introduced in 2004 and reached full coverage
in 2010 [14].
Because the incidence of ductal carcinoma in situ (DCIS) was not
registered before 1989, we limited our estimates of overdiagnosis
to invasive breast cancer. Data on the number of invasive breast
cancers were obtained from Stichting Medische Registratie for the
period 1975–1988 (ages 0–85 years) and the website of the
National Cancer Registry [15] in the Netherlands for the period
1989–2013 (ages 0–99 years). The number of screen-detected
breast cancers and interval cancers were collected centrally from
the screening organizations (1975–2009) [14] and the information
on the number of women living in the Netherlands were obtained
from Statistics Netherland (1975–2013) [16]. All data was provided
by calendar year and 5-year age groups (0–85 years) (see
supplement A). Fig. 1 presents the invasive breast cancer incidence
rate per 100,000 women-years by calendar period and age group.
2.2. Percentage of overdiagnosis
The percentage of overdiagnosis was deﬁned as ‘the percentage
of cancers detected during the screening period that would not present
symptomatically during one’s lifetime in the absence of screening’, in
line with previous work [17]. The nominator is the absolute
number of overdiagnosed cases estimated by subtracting the
cumulative incidence in the absence of screening from the
cumulative incidence in the presence of screening. In this study,
the cumulative incidence in the presence of screening is the
observed breast cancer incidence in the screened age group during
the screening period. The cumulative incidence in the absence of
screening could not be observed and was estimated by extrapola-
tion of pre-screening incidence trends. This approach is called the
cumulative incidence method or excess-incidence method [18,19].
The cumulative incidence approach needs to fulﬁll two conditions
to adequately adjust for lead time: 1) the follow-up after screening
cessation should include the maximum length of lead time, and 2)
the excess incidence during screening and the compensatory drop
after screening cessation should be estimated from women who
had the same screening participation rates and experienced the
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Fig. 1. Invasive breast cancer incidence rate per 100,000 women-years by calendar period.
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same screening practice [20,21]. In this study, we could not fulﬁll
the last condition – and probably also not the ﬁrst condition –
because we estimated overdiagnosis in periods with changing
participation rates and screening practice rather than in birth
cohorts [20]. Knowing that the participation and detection rates
increased over time, the overdiagnosis estimates are likely to be
overestimated [18,19]. Furthermore, the cumulative incidence
approach can result in negative overdiagnosis estimates when the
observed incidence in the presence of screening is lower than the
expected incidence in the absence of screening. Overdiagnosis can,
however, never be negative; therefore, values below zero are to be
interpreted as overdiagnosis being non-existent (no overdiagno-
sis). For the denominator we used the number of cancers detected
in women participating in the screening program, i.e. screen-
detected breast cancers and interval cancers (i.e. breast cancers
diagnosed in screened women during the interval between two
screening rounds) [17].
2.3. Models
We estimated overdiagnosis through extrapolating the pre-
screening incidence trend, using 69,120 different combinations.
These combinations varied with regards to the: type of regression
model used, end of the pre-screening period, and the age-groups
used to estimate the period trend (see Table 1). The percentage of
overdiagnosis was estimated for different starting and stopping
years of the screening period, screened age ranges, post-screening
age groups, and with/without adjustment for a trend in women
younger than 45. We adjusted for a trend in women younger than
45 years by dividing the expected incidence in the screened age
range by the relative excess, i.e. the ratio between the expected and
observed incidence, inwomenyounger than 45 [8]. The percentage
of overdiagnosis was calculated from absolute numbers and rates,
regardless of the type of regressionmodel used to estimate the pre-
screening trend.
3. Results
The percentage of overdiagnosis obtained by the different
assumptions to estimate the pre-screening trend ranges from
7.1% to 65.1% (Fig. 2). Fig. 2 shows that the range of estimates form
a multimodal distribution with peaks at 18%, 31%, 38% and 48%.
These peaks represent a group of small normal distributions,which
are obtained when stratifying for pre-screening period, screened
age range and adjustment for a trend in women below 45. Overall,
the estimates are not normally distributed and the median
estimated percentage of overdiagnosis is 33.6%
Table 2 presents the median percentages of overdiagnosis that
were derived from 34,560 model combinations without adjust-
ment for a trend in women younger than 45 for different
assumptions. The table shows that the end of the pre-screening
era has the largest inﬂuence on the percentage of overdiagnosis.
For the screened age range 50–74, the median percentage of
overdiagnosis is 14.3% for the estimates using 1975–1986 as the
pre-screening period and 39.6% for estimates using 1975–1988 as
the pre-screening period. Fig. 1 gives an explanation for this
difference: it shows a peak in the breast cancer incidence rate in
1986, which causes a higher trend and thus low overdiagnosis
estimates, and a drop in the breast cancer incidence rate in 1987,
which has an opposite effect on the trend and overdiagnosis
estimates. Table 2 also demonstrates that the overdiagnosis
estimates are higher for the screened age range 45–74 than for
the screened age range 50–74, which is caused by an increasing
breast cancer incidence in women aged 45–49 (see Fig. 1).
Other model speciﬁcations, i.e. type of regression model,
calculation method, age groups used to estimate period trend,
selected post-screening age groups, and starting and stopping year
of the screening period, also inﬂuence the percentage of
overdiagnosis, but to a smaller extent. For example, overdiagnosis
estimates decline with later starting and stopping years of the
screening era. The effect of age groups in themodel to estimate the
period trend seems to depend on two factors, namely the number
of groups and the speciﬁc age ranges in each group. If the number
of age groups in the model is smaller and if the screened age range
is grouped together (i.e. either 45–74 or 50–74), the overdiagnosis
estimates are lower. The estimates of overdiagnosis are also
slightly lower when linear regression is used instead of poisson
regression, overdiagnosis is calculated based on rate ratios rather
than absolute numbers and the post-screening age group was
75–84 years (10-year follow-up) rather than 75–79 years (5-year
follow-up).
Table 3 presents the median overdiagnosis percentage of
34,560 model combinations adjusted for a trend in women below
45. The adjusted overdiagnosis estimates are generally lower than
the unadjusted overdiagnosis estimates (30.2% versus 37.0%).
When comparing the results from Table 2 and 3, it becomes
apparent that the effect of each model speciﬁcation is similar for
Table 1
Assumptions used to estimate the percentage of overdiagnosis.
Category Options
Model
Type of regression model poisson regression, linear regression
End of pre-screening period 1984–1989 (the start of the pre-screening era is 1975 for all analyses)
Age groups to estimate period trend 20–45, 45–49, 45–74, 50–69, 50–74, 70–74, 75–79, 75–84, 80–84
Calculation
Screened age range 45–74, 50–74
Post-screening age range 75–79, 75–84
Starting year screening period 1990–2001
Stopping year screening period 2005–2009
Numbers absolute, rates
Risk adjustment no, trend in women aged 20–45
[(Fig._2)TD$FIG]
Fig. 2. Overdiagnosis estimates obtained from the extrapolation of pre-screening
trends using different model speciﬁcations.
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the unadjusted and adjusted estimates except for differences in the
end of the speciﬁed pre-screening period and the calculation of
overdiagnosis. The adjusted overdiagnosis estimates from Table 3
are higher than the unadjusted estimates from Table 2 when the
pre-screening period ends between 1984 and 1986 and vice versa
for the other pre-screening periods. Furthermore, in Table 2
overdiagnosis estimates are higher when based on rate ratios
rather than absolute numbers, but the opposite is true for the
adjusted estimates in Table 3.
4. Discussion
The percentage of overdiagnosis estimated through the
extrapolation of pre-screening trends varies from 7.1% to 65.1%
in this study. The period used to estimate the pre-screening trend
has the largest inﬂuence on the percentage of overdiagnosis, but
the inﬂuence of other factors should not be neglected.
4.1. Comparision with other studies
Several studies estimated the percentage of overdiagnosis using
the extrapolation of pre-screening trends. The estimates of these
studies vary from less than 0% [9] to 57% [5]. Because each study
uses a different denominator to estimate the percentage of
overdiagnosis, comparison of our estimates with previously
reported estimates is not straightforward. Our study, however,
shows that a wide variation in overdiagnosis estimates can even
solely be the result of using different assumptions for the
extrapolation of pre-screening trends, regardless of the denomi-
nator used to estimate overdiagnosis.
In addition, we showed that variation in overdiagnosis
estimates based on extrapolation of pre-screening trends depends
on assumptions such as the pre-screening period, the age groups
used tomodel the pre-screening trend, the screened age group, the
starting and stopping year of the screening era, adjustment for a
trend in women below 45, and the method to calculate
overdiagnosis (absolute numbers vs rates). The Independent UK
panel estimated the absolute number of overdiagnosed cases using
different models [11]. They found, similar to this study, that the
number of overdiagnosed cases decreased with a smaller screened
age range (50–64 vs 45–64), when the estimates were adjusted for
a trend in women below 45, and when linear regression was used
rather than poisson regression [11]. Furthermore, the UK panel
found an inverse relationship between length of pre-screening
period and number of overdiagnosed cases, which was not
observed in our study. Because this relation depends on the
Table 2
Median (quartile 1–quartile 3) percentage of overdiagnosis unadjusted for a trend in women <45.
Screened age range Total
45–75 50–75
Overall 43.0 (29.2–47.8) 35.0 (22.1–38.8) 37.0 (26.5–44.0)
Type of regression
Linear regression 42.6 (29.0–46.8) 34.1 (22.1–37.9) 36.5 (25.9–43.2)
Poisson regression 44.2 (29.4–48.6) 36.1 (22.0–39.7) 37.4 (27.2–45.1)
Calculation overdiagnosis
Based on rates 42.1 (28.2–46.8) 34.1 (20.9–37.7) 35.9 (25.6–43.0)
Based on absolute numbers 44.2 (30.3–48.8) 36.2 (22.9–39.8) 38.0 (27.8–45.1)
End of pre-screening period
1984 38.7 (36.7–40.9) 33.1 (31.0–35.4) 36.1 (33.0–39.0)
1985 29.2 (27.5–30.9) 22.0 (19.8–24.9) 26.6 (22.0–29.4)
1986 18.7 (17.1–20.3) 14.3 (12.2–16.9) 17.1 (14.2–19.2)
1987 47.9 (46.3–49.4) 38.2 (36.3–40.6) 43.8 (38.2–47.9)
1988 48.7 (47.1–50.2) 39.6 (37.7–41.7) 44.7 (39.6–48.7)
1989 46.8 (45.3–48.3) 38.2 (36.3–40.2) 43.1 (38.2–46.8)
Age groups to estimate period trend
<45, 45–74, 75–79, 80–84 43.3 (28.3–47.2) 38.5 (26.5–41.8) 39.9 (37.4–44.6)
<45, 45–74, 75–84 42.2 (27.5–46.4) 37.5 (25.8–40.9) 38.9 (26.6–43.7)
<45, 45–49, 50–69, 70–74, 75–79, 80–84 44.9 (30.8–48.9) 35.0 (21.5–38.2) 36.8 (25.7–44.9)
<45, 45–49, 50–69, 70–74, 75–84 43.8 (30.0–48.0) 34.0 (20.7–37.3) 35.8 (25.3–43.8)
<45, 45–49, 50–74, 75–79, 80–84 43.8 (29.7–48.3) 34.2 (30.3–37.7) 36.3 (25.5–44.1)
<45, 45–49, 50–74, 75–84 42.5 (28.9–47.4) 33.1 (19.7–36.7) 35.3 (24.6–42.8)
Post-screening age group
75–79 43.1 (29.5–47.8) 35.1 (22.3–38.8) 37.0 (26.8–44.0)
75–84 43.0 (29.0–47.7) 34.9 (21.8–38.8) 36.9 (26.3–44.0)
Starting year of screening era
1990 45.2 (31.2–49.8) 37.5 (23.8–40.8) 39.0 (28.8–46.0)
1991 44.9 (31.3–49.5) 37.2 (23.8–40.5) 38.8 (28.7–45.7)
1992 44.6 (31.0–49.2) 36.8 (23.6–40.1) 38.5 (28.5–45.3)
1993 43.9 (30.3–48.5) 36.0 (22.7–39.3) 37.7 (27.7–44.60
1994 43.5 (29.9–48.1) 35.5 (22.3–39.3) 37.4 (27.1–44.7)
1995 42.7 (28.9–47.3) 34.6 (21.6–38.1) 36.5 (26.4–43.4)
1996 42.1 (28.5–46.9) 34.2 (20.7–37.5) 36.0 (25.9–42.8)
1997 42.1 (28.5–46.9) 33.9 (20.2–37.6) 36.0 (25.6–42.9)
1998 42.1 (28.4–46.9) 34.2 (20.5–37.5) 36.0 (25.8–42.9)
1999 42.3 (28.5–47.2) 34.4 (20.7–37.8) 36.2 (25.9–43.1)
2000 42.3 (28.3–47.1) 34.1 (20.7–37.7) 36.1 (25.6–43.0)
2001 41.5 (27.2–46.5) 33.9 (20.7–38.5) 36.0 (24.9–43.1)
Stopping year of screening era
2005 44.7 (30.9–49.3) 36.9 (23.7–40.5) 38.7 (28.4–45.7)
2006 43.6 (29.8–48.2) 35.5 (22.3–39.2) 37.4 (27.2–44.4)
2007 43.1 (29.2–47.7) 35.0 (21.8–38.6) 36.9 (26.7–43.8)
2008 42.5 (28.7–47.2) 34.6 (21.3–38.2) 36.5 (26.2–43.3)
2009 41.8 (27.9–46.5) 33.7 (20.5–37.4) 35.8 (25.3–42.6)
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increase in the breast cancer incidence rates before the introduc-
tion of screening, it is likely to vary between countries. For
example, in the Netherlands the breast cancer incidence peaks at
1986 and drops in 1987 causing the lowest and highest
overdiagnosis estimates, when using these years as the end of
the pre-screening period. Unfortunately, it is unknown whether
this sudden ﬂuctuation is real or due to data errors (i.e. registration
issues). Our study also showed that overdiagnosis is inﬂuenced by
the age groups included in themodel and shows the impact of each
assumption in perspective. Unlike estimates for absolute numbers
of overdiagnosed cases, estimates for percentage of overdiagnosis
are not dependent on the number of women screened and
illustrate the impact of each assumption in a standardized way.
4.2. Limitations of utilizing pre-screening trends
The overdiagnosis estimates in this theoretical study range
from 7.1% to 65.1% and will therefore most likely cover the true
overdiagnosis estimate. The true overdiagnosis estimate however
remains unknown and is not necessarily represented by the
median overdiagnosis estimate of this study. The use of
extrapolation of pre-screening trends has two important
assumptions when it comes to estimating overdiagnosis. Firstly,
this method assumes a constant trend in the (breast) cancer
incidence rate after the pre-screening period ends [11]. The validity
of this assumption can be questioned because it requires that all
risk factors for (breast) cancer, both birth cohort and period
related, cause a constant increase in the (breast) cancer incidence
rate by calendar year. Besides the validity of this assumption, this
study showed that the magnitude of the constant increase is not a
set value and is highly dependent on the choice of the pre-
screening period. Secondly, the use of extrapolation of pre-
screening trends assumes that the quality of case ascertainment
remains the same [11]. This is unlikely given the improvements in
diagnostic procedures over the last decades.
In addition to the assumptions required to extrapolate pre-
screening trends, an adjustment for a trend in women younger
than 45 assumes that the breast cancer incidence rate increases at
the same pace in women in the screened age range and below 45.
In otherwords, the risk factors for pre- and postmenopausal breast
cancers are assumed to be similar or at least cause a similar
proportional increase in breast cancer incidence in each age group.
This assumption can be questioned, because some risk factors, i.e.
hormone-replacement therapy, only have an effect on post-
Table 3
Median (quartile 1–quartile 3) percentage of overdiagnosis adjusted for a trend in women <45.
Screened age range Total
45–75 50–75
Overall 35.5 (20.6–40.6) 28.0 (16.2–33.4) 30.2 (18.4–37.9)
Type of regression
Linear regression 33.1 (30.4–39.6) 26.4 (15.7–31.9) 28.7 (18.0–36.3)
Poisson regression 37.1 (30.7–41.8) 39.8 (16.6–34.7) 31.9 (18.9–39.2)
Calculation overdiagnosis
Based on rates 37.9 (29.2–40.7) 30.4 (22.1–33.6) 32.7 (26.3–38.3)
Based on absolute numbers 26.5 (16.0–40.2) 20.1 (11.4–32.5) 23.6 (13.7–36.5)
End of pre-screening period
1984 43.7 (39.7–50.1) 37.2 (33.4–42.7) 40.8 (36.4–46.7)
1985 31.6 (28.6–36.6) 24.8 (21.0–29.2) 28.8 (24.4–33.3)
1986 23.9 (19.1–36.4) 20.6 (14.5–29.2) 22.2 (17.4–32.7)
1987 32.7 (19.0–40.3) 26.4 (13.6–32.2) 37.7 (16.2–36.8)
1988 29.2 (12.6–39.7) 24.5 (8.6–32.2) 25.4 (10.5–36.5)
1989 30.5 (16.4–39.2) 25.5 (11.9–31.8) 26.8 (14.0–36.0)
Age groups to estimate period trend
<45, 45–74, 75–79, 80–84 35.2 (19.6–40.6) 31.6 (19.5–36.3) 32.4 (19.5–38.6)
<45, 45–74, 75–84 34.1 (18.9–39.9) 30.6 (18.8–35.5) 31.5 (18.9–37.7)
<45, 45–49, 50–69, 70–74, 75–79, 80–84 36.8 (21.8–41.4) 28.0 (14.9–32.6) 30.5 (18.9–38.3)
<45, 45–49, 50–69, 70–74, 75–84 36.0 (21.1–40.6) 27.1 (14.3–31.8) 29.6 (18.1–37.4)
<45, 45–49, 50–74, 75–79, 80–84 36.4 (20.9–40.9) 27.1 (14.2–32.1) 29.6 (18.0–37.8)
<45, 45–49, 50–74, 75–84 35.4 (20.3–40.0) 26.1 (13.5–31.3) 28.6 (17.2–36.9)
Post-screening age group
75–79 35.5 (20.9–40.6) 28.1 (16.6–33.4) 30.3 (18.9–37.9)
75–84 35.5 (20.1–40.6) 27.9 (15.6–33.3) 30.1 (18.0–37.8)
Starting year of screening era
1990 39.9 (23.8–44.3) 32.5 (19.7–36.8) 34.1 (22.0–41.9)
1991 39.6 (23.9–43.8) 32.2 (19.8–36.4) 33.9 (22.1–41.5)
1992 39.3 (23.7–43.5) 31.9 (19.6–36.0) 33.5 (21.9–41.2)
1993 38.4 (22.5–42.5) 30.8 (18.2–34.9) 32.5 (20.8–40.3)
1994 37.2 (20.8–41.4) 29.8 (16.7–33.9) 31.5 (19.2–39.1)
1995 36.3 (19.6–40.4) 28.8 (15.1–32.7) 30.4 (18.1–38.1)
1996 35.4 (18.6–39.4) 27.8 (13.8–32.0) 29.6 (17.2–37.3)
1997 34.9 (18.1–38.9) 27.3 (13.2–31.5) 29.1 (16.8–36.8)
1998 33.9 (17.0–38.2) 26.3 (12.0–31.3) 28.4 (15.5–36.3)
1999 33.5 (16.7–38.4) 26.0 (12.3–31.5) 28.5 (14.9–36.0)
2000 32.9 (15.9–37.6) 25.4 (11.1–30.8) 27.7 (14.0–35.5)
2001 30.9 (13.9–37.1) 23.3 (9.1–29.9) 26.4 (10.9–33.9)
Stopping year of screening era
2005 37.5 (23.0–42.4) 30.1 (18.6–35.3) 31.9 (20.7–39.8)
2006 36.2 (21.2–41.0) 28.5 (16.8–33.8) 30.5 (18.9–38.3)
2007 35.8 (20.3–40.5) 28.1 (15.7–33.3) 30.1 (18.1–37.8)
2008 35.3 (19.5–39.9) 27.7 (15.1–32.8) 29.7 (17.6–37.3)
2009 34.1 (18.6–39.0) 26.5 (14.1–31.7) 28.7 (16.6–36.3)
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menopausal breast cancers. Adjustment for a trend in women
younger than 45 may however be useful when the unadjusted and
adjusted trends are compared. Similar overdiagnosis estimates for
unadjusted and adjusted trends may indicate the more reliable
trends and therefore more reliable overdiagnosis estimates.
Another way to obtain more reliable and stable trends is the
utilization of 5-year smoothed averages.
Another limitation of using of pre-screening trends is that it can
often only be used to estimate overdiagnosis from invasive cancer.
DCIS ismore likely to be overdiagnosed than invasive breast cancer.
However, in most countries DCIS was not registered before the
introduction of mammographic screening and can therefore not be
included in the overdiagnosis estimate. This leads to an
underestimation of overdiagnosis.
4.3. Limitations of the current study
Besides the limitations of the assumptions needed to extrapo-
late pre-screening trends, other factors may cause an overestima-
tion of the range of overdiagnosis estimates provided in this study.
We estimated overdiagnosis in a population that is still screened,
which leads to an inadequate adjustment for lead time. In order to
adequately adjust for lead time and obtain a reliable estimate of
overdiagnosis using a cumulative incidence approach, overdiag-
nosis should be estimated in a population in which screening has
ceased and is followed up until the maximum length of lead time
after screening has ceased. Such a population can be obtained
either by measuring overdiagnosis in birth cohorts that stop
screening at a certain age [20] or by measuring overdiagnosis in
countries that once screened for (breast) cancer but have ceased
screening. Because we could not adequately adjust for lead time in
this study, the overdiagnosis estimates are most likely over-
estimated. This is also reﬂected by the decreasing percentage of
overdiagnosis with later starting and stopping years of the
screening period: overdiagnosis is expected to increase within
this period based on advances in technology (i.e. digital
mammography) [22]. However, this does not occur because the
compensatory drop starts to compensate the excess cases from
about 2002 onwards in the age group 75–79 and even later in the
age group 80–84. Other overdiagnosis estimates from the
Netherlands with a more adequate adjustment for lead time have
also reported estimates towards the lower end of the range of
estimates presented here and also included DCIS [12,23].
Another limitation of this study is that we analyzed the data for
the whole population of the Netherlands rather than per region,
even though screening was implemented in different years in
different regions/municipalities. Incidence trends per region will
prevent dilution and show a more pronounced shift in the breast
cancer incidence after introduction of mammographic screening
[24]. The effect of such analyses on the overdiagnosis estimate is
not straightforward, because the compensatory drop may also be
more pronounced and the denominator depends – just as the
number of overdiagnosed cases – on the implementation. Analyses
per region are, however, likely to result in more accurate
overdiagnosis estimates.
Furthermore, we would like to point out that we used the
cumulative incidence method [18], also called excess incidence
method [19], to estimate the percentage of overdiagnosis.
Extrapolation of pre-screening trends is also used to create a
reference population for estimating overdiagnosis [25,26] and to
estimate the percentage of overdiagnosis using the lead time
approach [27,28]. It can be expected that the inﬂuence of the pre-
screening trends on the percentage of overdiagnosis in such
studies is smaller than the range of estimates presented here [25],
because the current estimates are also affected by an inadequately
measured drop after leaving screening.
4.4. Conclusion
To conclude, extrapolation of pre-screening trends are com-
monly used to estimate the percentage of overdiagnosis. This study
shows that overdiagnosis estimates are heavily dependent on the
assumptions made, especially those for the pre-screening period.
Researchers should acknowledge the limitations of extrapolation
of pre-screening trends and adjust adequately for lead time.
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